Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you! Much appreciated.
Me too as they say. I see this as a great opportunity. We have been de risked since the last time we were at these levels.
Dr Missling is a competent CEO and with the excellent results as what we have (by his leadership I may add) can get A-273 approved for Alzheimer, PDD, Retts, FragileX. So far so good. BP value will likely be effected when approval comes but the plus side and what's important is people are helped:)
Ah gotcha yes a bedtime dosing.
I heard it as SAP statistical analysis protocol. My take is they followed the planned test study and found A-273 checked all the boxes. Starts@44:35 Got to listen carefully though.
https://video.wixstatic.com/video/79bcf7_6566f1d485d2424eadf745c64a05ff7a/480p/mp4/file.mp4
Good post! This is where the rubber meets the road. A very real threat in BP's future value. We get excellent trial results and it's an all out effort to tank the company. Hoping for some honest analysts.
Our MOA so disruptive that it will cause losses of billions in profits selling worthless drugs, loss of advertising revenue from Big Pharma, invalidation of decades of research and billions wasted, etc. The fact that not one mainstream media outlet picked up the story says a lot. They've been gushing over Biogen's results for weeks so one would think that a company beating those results would be breaking news all over but all we hear are crickets.
Yes BP's definitely know now. We have a lot of new bears here. Biogen got bested good.
We were just handed superior Alzheimer's results with more indications to come. I consider this a long term buy and hold. I've been adding again as of late.
Anavex will likely take market share of other companies in this space and that's a rub. My take away this morning is if your marketing an infusion drug your in trouble.
That was bad. Hopefully he is still well. The elderly are precious to their families.
I imagine reading a book, playing piano and painting. Dr Missling can likely give more in-depth report now that trial has finished. I hope A-273 gives a lot of people long term healing. Good stuff.
Exactly, here's what they all saw and it's as crisp and clear as a cold December morning. Huge news.
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE
Yeah just look at donepizil. Early approval.
We have a winner!! A-273 may just set the new standard of care.
I believe they are afraid of a cure as funding would dwindle. Anavex as we have seen has some uphill to go but positive news trumps all. Big organizational donors get all the accolades.
Alzheimer's is a very hard nut to crack so I'll go out on a limb and say longs are quite pleased with results. That's really all that matters.
Your trying too hard. Trial was and is very successful against a really tough disease. Read the 8k.
I believe it's not the drop as much as the rise up that has them worried. Next week could be fun.
They are majoring in minors. The data 45% @ 48 weeks beats Biogen's mab and that's what matters. And then there's the shorts.
I believe a week ago you posted secondary endpoints would not be met so there's that. Primary AND Secondary have been met per 8k. Biogen is verrry nervous today imo.
Yes. Three more indications to power it up!
It's the shorts who have their math wrong.
They are trying to instill doubt. The power of A-273 is too great.
Anavex ushers in a new standard of care! What a headline.
I believe the timeline for a FDA response is 45 days.
Real analysts will soon pick up on today's great news.
AF by another name.lol
Yep we got this. A-273 is the real deal. ANAVEX®2-73 treatment slowed cognitive decline by 45% compared to placebo at 48 weeks. Biogen received approval at 27%.
News will just get out people talk others listen. Media will most likely spread it. It brings hope.There may even be a interview or two. This is big time stuff.
Medicare will jump on this due to the cost savings. A pill would be covered under a prescription drug plan not regular medicare.
That's right thank you Lord!!!
Ditto! Significant news!! Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL
Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results
Plan to Meet with Regulatory Authorities to Determine Next Steps
Wow Remdesiver causes acute kidney injury. No thank you! One thing to note is remdesiver failed miserably it's first covid-19 trial. B needs another fair shot.
Roche presented full results of twin trials at an Alzheimer's meeting in San Francisco after announcing in November that the drug had failed in the two trials.
So failure was announced prior to CTAD. AVXL up next.
Thanks. I see the chart displays Anavex 3-71 for AD so no changes. Good to see.
He clearly has the data and more.
“This is an exciting time in neuroscience and rare disease drug development and we remain on track for the readout of the placebo-controlled ANAVEX®2-73 Phase 2b/3 Alzheimer’s disease clinical trial, a condition of significant unmet need and economic burden for which there are only limited approved pharmacological treatment options,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Our recent progress highlights the potential of our clinical Precision Medicine SIGMAR1 platform and portfolio, and we look forward to sharing additional program and data updates.”
Nice to see this paper. Thanks StockJumper!
https://cbdstconference.com/wp-content/uploads/2022/09/2022CBDSTconference-abstract-363.pdf
Most of the 509 P2B/3 trial participants have enrolled in the open label extension. Why would they... why would care givers keep on with it. Easy answer to me is because of the benefit it provides.
Picked up some today also sure didn't expect this kneecapping though. A good opportunity for new investors to get in. Looking forward to data.